Helpline 0808 800 3333 or contact us
For disability information call free
0808 800 3333 or contact us
0808 800 3333
Anything else? Other ways to contact us
Baclofen is a muscle relaxant. It can relieve the stiffness caused by spasticity (tight and stiff muscle tone).
You can take Baclofen by mouth in a low dose. Some patients do not respond well to oral medication and can develop side-effects.
It is often preferable to implant a system that can accurately and safely deliver drugs directly into the nervous system. Delivering the medication into the spinal cord, where it is needed, can improve results on smaller doses than with oral medications. This can also minimise some of the potential side-effects.
Baclofen is delivered directly into the spinal fluid, by a pump implanted under the skin of the abdomen and connected to a thin flexible catheter. The catheter is tunnelled beneath the skin into the intrathecal space in the spinal cord, where it delivers a precisely controlled dose of the medication.
The pump can be programmed to suit the individual and can provide a higher dose of medication at different times of day, if required. The pump is about the size of an ice hockey puck, but can sit in the abdominal cavity.
Children as young as 5 have received ITB, but it does depend on the size of the cavity in the abdomen in which the pump sits.
ITB can give more independence in feeding and dressing. It can also make sitting and transferring more comfortable.
With cerebral palsy some of the specific benefits are:
Side-effects of Baclofen can include:
Like all surgery, ITB carries risks such as infection, bruising, bleeding, spinal fluid leakage, headache and discomfort. The medical team will discuss these with you before the operation.
Some potential risks include those associated with the pump. For example, the tube may move, kink or break, or part of the pump may fail to work.
ITB is not suitable for everyone who has cerebral palsy or a neurological condition. For example, it does not help people with:
It is recommended for severe generalised spasticity.
There is a clear screening process. The final stage, before the pump is inserted, is to give patients a test dose of Baclofen direct into the spine via a lumbar puncture. This lasts 4 hours and ensures that this method of delivering the drug is suitable. This test dose will help the medical team decide whether you or your child will benefit.
The key to the success of ITB is working with the medical team. It's important to attend all outpatient visits for refills and follow-up assessment. Follow-up visits vary from weeks to months depending upon the dose of medication.
Treatment can involve intensive physio and occupational therapy in the first few weeks after the operation. Therapy may continue for several months.
The pump is made from titanium and the catheter from silicone. These materials are unlikely to cause an adverse or allergic reaction.
The battery within the pump can last several years. Your medical team will monitor the battery life and can schedule a pump replacement before the existing battery expires. The pump also has an alarm which will prompt you to see the medical team before the battery runs out.
There have been several research papers published around ITB and the administration of Baclofen. For further information see ITB Therapy published by Medtronic.
Funding for ITB can be inconsistent. Almost all medical and surgical treatments are funded by your Primary Care Trust (PCT). The ecision is based upon factors including:
Once you or your child have been assessed as suitable for ITB Therapy, the medical team contacts the relevant PCT for an agreement to fund. This process may take months on a waiting list until agreement is made. Occasionally funding is refused. If so, there is the right to appeal.
Hi - interested to hear from other adults with CP.
Hi I am 36 and have CP effecting my lower limbs.I had both of my Achilles' tendons lengthened in 1987.
Find out how @Scope is helping people to feel more confident about disability. Help us #EndTheAwkward http://bit.ly/2egoZQx